Mounjaro®
Starting from £179.99/mo
Start journey Learn moreOne dose of Mounjaro in the UK private market costs somewhere between roughly £37 and £94, depending on the strength you're prescribed and the provider you use — though that single-pen figure tells you very little without knowing what's actually included in the price. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber must assess your suitability before any supply can lawfully happen, and any legitimate price should reflect that clinical step. Eli Lilly raised the UK list price of the highest doses significantly from 1 September 2025, with reported private-market prices now ranging from around £149 to £375 per monthly pen across strengths and providers — figures that have been widely reported since Lilly's announcement. What sits behind any headline number varies considerably, and that gap matters more than most people expect.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people searching for the cost of a single Mounjaro dose have already spotted a range of figures and are trying to reconcile them. That's a reasonable thing to do. The confusion usually comes from one source: different providers quote prices at different points in the process. Some figures cover the pen alone. Others fold in a consultation fee separately billed at checkout. A few include delivery as standard; many charge for it. Aftercare (the clinical support available if you have a side effect, need a dose query answered at the weekend, or want your progress reviewed before reordering) is sometimes a paid add-on and sometimes absent entirely.
Then there's the strength variable. Mounjaro runs from 2.5 mg up to 15 mg, titrated by your prescriber in steps that typically span several months. The mid-range doses cost noticeably more than the starter pen, which means a per-dose comparison only holds if you're comparing the same strength. A 2.5 mg pen from one provider and a 10 mg pen from another are not comparable on price alone. The NHS medicines information page for tirzepatide outlines what the medicine is and how it works; it does not publish private prices, for obvious reasons.
A common misconception is that a lower headline price means a lower total cost. In practice, a consultation fee added at checkout, a delivery charge, and a paid clinical-review call can turn a seemingly cheaper pen into a more expensive month than one transparently priced from the start. If you want to understand how much each dose of Mounjaro actually costs, breaking it down by strength is a more reliable way to plan your budget than relying on a single headline figure. Worth factoring in before deciding.
Mounjaro is not a flat-price medicine. Each strength is a physically different pen, and each carries a different price point in the private market. As a prescription that typically progresses from 2.5 mg through 5, 7.5, 10, 12.5 and up to 15 mg, the cost of one dose in month one is genuinely different from the cost of one dose in month six. Providers who advertise a single attention-catching figure are usually quoting the starter-dose pen. That can create a planning mismatch: the treatment cost you budget for at the start may not reflect what you'll pay once titrated to a therapeutic dose.
NICE's appraisal of tirzepatide, TA1026, sets out the clinical basis on which the medicine is recommended, including the expectation that dose progression is guided by tolerability and response, not a fixed schedule. That's relevant to cost because no prescriber can tell you in week one exactly which dose you'll end up at. Planning for the upper end of the dose range is prudent.
For a practical breakdown of how pricing shifts across the full schedule, the Mounjaro pricing page on the nume site covers the full picture by dose. It's more useful than any single-dose figure in isolation.
At nume, one price covers the consultation, the prescription, the medicine, next-working-day DPD delivery and ongoing clinical aftercare. No separate billing for the consultation. No delivery added at checkout. No subscription you have to cancel. Every repeat order gets its own clinical re-review by a GPhC-registered Independent Prescriber, that review isn't automated. You can verify our pharmacy on the GPhC register (registration 9012878) in about thirty seconds.
We're not the cheapest option. That's a deliberate choice. The infrastructure behind safe, clinically supervised dispensing (qualified prescribers, regulated supply chain, real aftercare) has a cost, and we don't think the right response to that cost is to strip out the parts that protect you. Our prescribers see patients who transferred from cheaper services because something went wrong, or because nobody was available to answer a question at 9pm on a Saturday. We'd rather be upfront about what we include than compete on a headline figure that excludes it.
Current treatment pricing is shown on the consultation and treatment page; we don't list per-pen prices in our content because the right dose, and therefore the right cost, is something your prescriber determines. You can also read more about what Mounjaro costs overall if you're at the early research stage. Some patients also ask specifically about what is in the golden dose of Mounjaro, particularly once they are further along in their titration journey.
The MHRA has issued clear public warnings about counterfeit weight-loss pens, including a significant enforcement operation in late 2025 that uncovered an illicit UK manufacturing site producing fake tirzepatide pens. Seized products have included pens contaminated with insulin, a drug that, injected without a diabetes diagnosis or clinical supervision, can cause life-threatening hypoglycaemia. The MHRA's Yellow Card scheme allows people to report suspect sellers, and that reporting matters.
The pattern behind counterfeit supply is consistent: prices well below the market, sellers operating through social media, no clinical assessment, supply without a valid prescription. A per-dose price that looks like a bargain, from a seller you can't verify on the GPhC register, is not a bargain. It's a risk. For a prescription medicine, the right question isn't which option is cheapest, it's which option comes with a verified pharmacy, a real prescriber, and a supply chain you can trace.
If you're ready to find out whether Mounjaro is clinically appropriate for you, the straightforward starting point is a free consultation with our prescribers. Reviewed the same day. No commitment until you're approved and happy to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.